Saturday, June 21, 2014

BSD Medical - Brings the Heat


Note:  This report was writtn by a friend of Growth Stock Insider (Tricia Ross of Financial Profiles).  The information was obtained from sources believed to be reliable but are not guaranteed either by the author or Growth Stock Insider.

BSD Medical Corporation (NASDAQ: BSDM) is a pioneer in developing, manufacturing and servicing groundbreaking medical systems to treat cancer using heat therapy.  Its strong competitive position is based on superior technology and product design.  The company is led by a successful, proven management team with a combined 9 decades of Fortune 500 and start-up medical-industry experience. BSD has no debt and an improving bottom line that is moving the company toward profitability.




(Quarterly Revenue)


BSD is poised to benefit from current healthcare trends.  The Company’s systems are closely aligned with the Affordable Care Act’s drive for quality care at lower costs. 

BSD’s MicroThermX® Microwave Ablation System is a transformative opportunity that delivers precision-guided microwave energy to destroy tumors. The MicroThermX is cleared for marketing in the U.S. and many other countries throughout the world. Microwave ablation treatment is less invasive than surgery and effective for certain cancers.

Large and growing market.  The global market for soft tissue microwave ablation is estimated at $510 million and projected to grow 18% annually.  The MicroThermX uses innovative, high-end disposable antennas in each treatment, which can provide significant ongoing revenues with attractive profit margins as the installed base grows.



BSD has an exclusive multi-million dollar distribution agreement with global medical device leader Terumo Corporation to market MicroThermX in 100 countries in Europe, Western Asia and Africa with a market potential that exceeds $1 billion.  Terumo is implementing a well-planned, comprehensive marketing strategy for the MicroThermX that is aimed at geographic expansion and building credibility within the clinical community, resulting in gaining sales traction in the Western European countries. Terumo plans to expand into Eastern European markets with the Middle East to follow. Terumo is also sponsoring several studies with the MicroThermX.

BSD hyperthermia products are designed to increase the effectiveness of primary cancer treatments, such as radiation and chemotherapy by delivering precision-focused microwave or radio frequency energy into diseased sites. BSD’s hyperthermia products are approved in the U.S. and many other countries throughout the world. The Company has exclusive agreements for distribution in Taiwan, South Korea, China and Europe.

Since gaining marketing approval for its hyperthermia products in Taiwan in February 2014, BSD has shipped three BSD-2000 Hyperthermia Systems ordered by its exclusive distributor in that country.  The Company expects to ship a fourth system to Taiwan by its August 31 fiscal year end. 

BSD’s cancer treatment systems have been used to treat thousands of patients throughout the world.  The Company also has received many awards, including the Frost & Sullivan “Technology Innovation of the Year Award” for cancer therapy devices, which was awarded for the development of the BSD-2000 Hyperthermia System.


This blog contains certain forward-looking statements with respect to BSD Medical Corporation.  Forward-looking statements are statements that are not descriptions of historical facts and include statements regarding management's intentions, beliefs, expectations, plans or predictions of the future, within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements include risks, uncertainties and contingencies, actual results may differ materially and in adverse ways from those expressed or implied by such forward-looking statements. Additional information concerning Apollo Medical Holdings, Inc. and its business including additional factors that could materially and adversely affect its financial results including, but not limited to, the risks described in its annual report on Form 10-K and in other filings with the SEC.



No comments:

Post a Comment